Stocks › ALC
Alcon Inc. (ALC) stock analysis
SKIP 0% confidence · analysed Sep 4, 2026
This analysis is from Sep 4, 2026 and may be out of date.
On Sep 4, 2026, our model rated Alcon Inc. (ALC) SKIP with 0% confidence at a price of $72.08. That means the signals cancel out; the model sees no clear edge either way.
Technical picture
The 14-day RSI is 37. Momentum is soft: below the neutral 50 line, but not yet oversold.
MACD is below its signal line, so short-term momentum is pointing down.
The price is above its 50-day moving average but still below the 200-day: a short-term recovery inside a longer-term downtrend.
Volume is only 0.6x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $87.21 and the swing low is $61.83; traders often treat these as resistance and support.
Price is sitting in a bearish order block, a zone where large sellers stepped in before, so upside may stall here.
Fundamentals
The PEG ratio is 1.26, which looks reasonably priced for its growth.
The company reports a profit margin of 5.9% and revenue growth of +8.7%.
In its latest quarter it earned $0.84 per share, which beat the $0.76 analysts expected, with revenue +9.4% year over year.
Wall Street's average rating is 1.6 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $85.24.
The next earnings report is expected around Nov 10, 2026; prices often move sharply around earnings.
Research notes
Alcon’s bull case remains intact on recent operating momentum: Q2 2026 EPS of $0.84 beat estimates of $0.77, revenue rose 8.0% year over year, and the new UNITY M surgical microscope launch in the U.S. and Japan adds a near-term product catalyst. The bear case is mostly valuation and execution risk: after a strong run, the stock has been near its 52-week high and recent price action has been choppy, with one source noting a small dip in Zurich even after the earnings beat. Fresh attention also came from reports tying Alcon to new U.S. Medicaid drug-pricing agreements, though the direct impact on the eye-care business is still unclear. Latest public information and price action are broadly consistent with the prior positive view, with fundamentals improving and the stock still holding near elevated levels despite a modest pullback.
The model's one-paragraph read
No clear edge (SKIP) — composite score -0.00 (SKIP). Technicals: RSI 36.97, MACD bearish, price above SMA50. Fundamentals: PEG 1.26, margin 5.9%, revenue growth 8.7%. Financial results: YoY revenue +9.4%, last EPS surprise +10.5%, next earnings 2026-11-10. Smart Money Concepts: ranging / no clear structure, price retesting a bearish order block, sitting inside an unfilled bearish fair value gap. FinGPT news read: positive. Memory: 1 prior look(s); 0% of directional calls matched later price. Internet research: Alcon’s bull case remains intact on recent operating momentum: Q2 2026 EPS of $0.84 beat estimates of $0.77, revenue rose 8.0% year over year, and the new UNITY M surgical microscope launch in the U.S. and Japan adds a near-term product catalyst. The bear case is mostly valuation and execution risk: after a strong run, the stock has been near its 52-week high and recent price action has been choppy, with one source noting a small dip in Zurich even after the earnings beat. Fresh attention also came from reports tying Alcon to new U.S. Medicaid drug-pricing agreements, though the direct impact on the eye-care business is still unclear. Latest public information and price action are broadly consistent with the prior positive view, with fundamentals improving and the stock still holding near elevated levels despite a modest pullback. Reference price $70.97; no trade levels (SKIP).
Past ratings for ALC
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Sep 4, 2026 | SKIP | 0% | $72.08 | — | |
| Sep 2, 2026 | SKIP | 7% | $72.89 | -1.1% |
"Move since" compares each call's price with the latest analysed price.
Other Healthcare stocks we cover
AMGN · AMRX · ANIP · ASTH · ATEC · ATRC · BCRX · BDX · BIIB · BMY · BSX · CNC
Frequently asked questions
Is ALC a buy right now?
As of Sep 4, 2026, our automated model rates Alcon Inc. (ALC) SKIP with 0% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
When does Alcon Inc. report earnings next?
The next earnings report is expected around Nov 10, 2026.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.